NewsBenzingaCRISPR Therapeutics Reports 65% ANGPTL3 And 63% Triglyceride Reductions With CTX310 In Phase 1b Trial For Severe Hypertriglyceridemia; Well Tolerated, With No Treatment-Related Serious Adverse Events And No Clinically Relevant Elevations In Liver... CRISPR Therapeutics Reports 65% ANGPTL3 And 63% Triglyceride Reductions With CTX310 In Phase 1b Trial For Severe Hypertriglyceridemia; Well Tolerated, With No Treatment-Related Serious Adverse Events And No Clinically Relevant Elevations In Liver... Benzinga 2026.11.09 14:17 (GMT+0) Open on Benzinga Other news SpaceX AI-Chip Debt Sale May Start This Week: Report Part of SpaceX's $40 Billion AI Chip Debt Financing May Be Sold as Soon as This Week Uber and Zipline’s drone delivery service takes off in Texas, with dozens of cities to follow Pantera Capital Leads $30M Series A for Stablecoin Payments Firm Codex at $130M Post-Money Valuation Dear Nvidia Stock Fans, Mark Your Calendars for November 18 Meta launches Direct, a standalone messaging app for Instagram